August 7, 2026 04:39 AM EDT

Blos­somHill, Lati­go cap four-IPO week with com­bined $496M haul

A can­cer biotech vy­ing for a piece of As­traZeneca’s can­cer ter­ri­to­ry and a pain spe­cial­ist chas­ing Ver­tex’s land­mark non-opi­oid …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Think we're worth reading - tell Google.